Keyword: Bill and Melinda Gates Foundation
Otsuka plans to acquire Visterra and its antibody engineering platform for $430 million in cash, as it aims to build out its discovery efforts.
PATH partnered with SD Biosensor to develop an in vitro diagnostic to screen out patients that may be harmed by common malaria treatments.
Alta Partners raised $130 million for its ninth venture capital fund, focusing on biotech and healthcare technology companies.
A project that aims to rev up the search for drugs to treat antimicrobial-resistant infections has picked up two more deep-pocketed backers.
Gregory Verdine’s FogPharma raised $66 million in series B financing, with hopes to bring its first product to the clinic by the end of next year.
The Bill & Melinda Gates Foundation has teamed up with big pharma Novartis and its experimental drug for certain diarrheal diseases.
Arsanis is gunning for a $58 million IPO as it seeks a new cash load for its work on using monoclonal antibodies for infectious diseases.
The Bill & Melinda Gates Foundation is investing up to $40 million spur research into the use of TCR-based therapeutics to treat tuberculosis and HIV.